NewEdge Advisors LLC Has $493,000 Stock Position in Edwards Lifesciences Corporation $EW

NewEdge Advisors LLC reduced its holdings in Edwards Lifesciences Corporation (NYSE:EW) by 77.3% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 6,161 shares of the medical research company’s stock after selling 20,977 shares during the period. NewEdge Advisors LLC’s holdings in Edwards Lifesciences were worth $493,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of EW. Groupama Asset Managment acquired a new stake in shares of Edwards Lifesciences during the first quarter worth approximately $1,337,000. Segall Bryant & Hamill LLC purchased a new stake in Edwards Lifesciences in the 1st quarter worth approximately $1,711,000. CTC Alternative Strategies Ltd. purchased a new stake in Edwards Lifesciences in the 1st quarter worth approximately $328,000. Vestor Capital LLC boosted its stake in shares of Edwards Lifesciences by 55.2% during the 1st quarter. Vestor Capital LLC now owns 2,940 shares of the medical research company’s stock valued at $235,000 after buying an additional 1,046 shares during the period. Finally, J. Derek Lewis & Associates Inc. boosted its stake in shares of Edwards Lifesciences by 145.1% during the 1st quarter. J. Derek Lewis & Associates Inc. now owns 9,290 shares of the medical research company’s stock valued at $744,000 after buying an additional 5,499 shares during the period. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 23,145 shares of the business’s stock in a transaction dated Wednesday, May 27th. The stock was sold at an average price of $86.42, for a total value of $2,000,190.90. Following the completion of the sale, the vice president owned 98,611 shares of the company’s stock, valued at $8,521,962.62. The trade was a 19.01% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Daniel J. Lippis sold 619 shares of the company’s stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $92.03, for a total value of $56,966.57. Following the sale, the vice president owned 40,034 shares of the company’s stock, valued at approximately $3,684,329.02. This trade represents a 1.52% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 25,570 shares of company stock valued at $2,219,390 over the last three months. 0.31% of the stock is currently owned by insiders.

Edwards Lifesciences Stock Performance

EW stock opened at $89.89 on Friday. The firm has a 50 day moving average of $89.21 and a two-hundred day moving average of $84.67. Edwards Lifesciences Corporation has a 12 month low of $72.30 and a 12 month high of $96.29. The company has a market capitalization of $51.76 billion, a price-to-earnings ratio of 51.66, a P/E/G ratio of 2.26 and a beta of 0.85. The company has a quick ratio of 3.77, a current ratio of 4.52 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share for the quarter, beating analysts’ consensus estimates of $0.74 by $0.04. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. The business had revenue of $1.74 billion for the quarter, compared to the consensus estimate of $1.70 billion. During the same quarter last year, the firm earned $0.67 EPS. Edwards Lifesciences’s revenue for the quarter was up 13.6% on a year-over-year basis. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. As a group, equities analysts anticipate that Edwards Lifesciences Corporation will post 3 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on the stock. BTIG Research upped their price target on shares of Edwards Lifesciences from $100.00 to $110.00 and gave the stock a “buy” rating in a research note on Tuesday, June 30th. Royal Bank Of Canada lifted their price objective on Edwards Lifesciences from $100.00 to $110.00 and gave the company an “outperform” rating in a research report on Monday, July 13th. Wall Street Zen downgraded Edwards Lifesciences from a “buy” rating to a “hold” rating in a research note on Saturday, July 4th. Robert W. Baird upped their target price on Edwards Lifesciences from $85.00 to $87.00 and gave the stock a “neutral” rating in a research report on Friday, April 24th. Finally, TD Cowen reaffirmed a “buy” rating on shares of Edwards Lifesciences in a research note on Tuesday, July 21st. Seventeen equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $100.27.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.